Richard L. Sherman

Richard maintains an active worldwide legal and strategic business consulting practice focused on life sciences companies. He has served as general counsel for private and public development stage pharmaceutical and biotechnology companies for over 45 years, including Marinus Pharmaceuticals, Inc., TetraLogic Pharmaceuticals Corporation and Actinium Pharmaceuticals, Inc. He spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the law firm of Pepper Hamilton LLP (1990-1992), and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group in New York. He has been a venture partner in SCP Private Equity Partners, SCP Vitalife Partners, and CIP Capital LP, investment firms with a focus on development stage life science and technology companies. Mr. Sherman has served on the board of directors of a number of public and private for-profit companies in the United States and Canada, including Biophage, Inc. (Chair), CytoMed, Inc., Functional Technologies Corp. (Chair), IBAH, Inc., Kenna Technologies, Inc., Leversense LLC, Mera Pharmaceuticals, Inc., Sparta Pharmaceuticals, Inc., Immunomedics, Inc., Hawaii Biotech, Inc., and PONTiS Orthopaedics LLC., as well as many non-profits, including The Sbarro Health Research Organization, Aloha Medical Mission, American Music Theater Festival (Chair) and SCA, Inc. (Chair). Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor in 1971.